"small cell cancer" trang 12 - tải miễn phí từ tailieunhanh
Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
8    61    1
Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer

Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer
9    58    1
Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
9    43    2
The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer

The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer
14    52    1
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
7    39    1
Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer

Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
7    36    1
Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy

Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
6    30    1
Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: A meta-analysis of published studies involving 32 studies

Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: A meta-analysis of published studies involving 32 studies
13    37    1
The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: Based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume

The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: Based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume
10    43    1
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: Results of a phase II trial (MOVE trial)

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: Results of a phase II trial (MOVE trial)
6    27    1
The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer

The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
6    36    1
Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients

Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients
8    43    1
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
8    46    1
Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer

Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer
8    40    1
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
10    39    1
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
12    38    1
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
9    37    1
Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas

Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas
9    33    1
FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis

FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis
10    34    1
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
5    41    1